Preclinical evidence, particularly in glioma, supports the hypothesis that mutIDH assumes a “passenger,” rather than a “driver,” role soon after the development of the IDH mutation likely due to initiating methylation changes being preserved by epigenetic memory and consequent acquisition of additional driver mutations (80, 81). This evidence concerns the gene IDH1 and glioma.